Verastem announces analyses of avutometinib plus defactinib outcomes to be presented at IGCS 2026
VSTM•Verastem said new molecular profiling and external control arm analyses of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer will be presented at IGCS 2026. The company reported an 18% objective response rate (ORR) and 13-month median progression-free survival in triple wild-type disease, and a 44% ORR and 94% disease control rate in a Japanese study.
1. Study analyses planned
Verastem announced that new RAMP 201 molecular profiling and external control arm analyses describing outcomes for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer will be presented at IGCS 2026.
2. Reported study outcomes
Verastem said the combination achieved an 18% ORR and 13-month median progression-free survival in triple wild-type low-grade serous ovarian cancer. In a Japanese study, it achieved a 44% ORR and a 94% disease control rate. The company also said the treatment showed higher ORR and progression-free survival versus conventional care in low-grade serous ovarian cancer.
